Latest Headlines

Latest Headlines

MorphoSys bets on Emergent BioSolutions' cancer contender in $183M deal

German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.

Merck KGaA tackles hot immuno-oncology field in partnership with MorphoSys

MorphoSys has notched another high-profile pharma partnership on its belt of antibody deals, and it's set its sights on immune checkpoint inhibitors. With this pact, Merck KGaA is also staking out a position on the growing roster of companies scrambling to find a profitable place for itself in immuno-oncology.

Novartis' 'breakthrough' muscle drug is worth $4B, if you ask MorphoSys

Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $4 billion a year.

MorphoSys grabs $126M for clinical trial work

The money will be used, in part, to pay for a mid-stage study of MOR208, its anti-CD19 antibody for chronic lymphocytic leukemia as well as new studies of MOR202, an anti-CD38 antibody currently in a Phase I/IIa clinical trial in multiple myeloma.

Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal

Celgene has decisively stepped in to partner on an early-stage myeloma and leukemia drug in MorphoSys's pipeline, paying $92 million upfront, a $60 million premium for a stake in the company and offering to cover a substantial portion of the R&D budget for the antibody targeting the CD38 molecule.

GlaxoSmithKline grabs PhII rheumatoid arthritis drug in $579M MorphoSys deal

GSK is paying about $28 million of that upfront and will take over all further R&D and commercialization efforts. MorphoSys snags a double-digit royalty stream from any sales that might come along with up to $550 million in milestones.

MorphoSys zeroes in on partner for blockbuster hopeful against arthritis

New clinical data have bolstered MorphoSys CEO Simon Moroney's blockbuster hopes for the biotech's experimental antibody against rheumatoid arthritis (RA), and the chief executive is hunting for a partner to aid in developing the drug that he believes could generate north of $1 billion in annual sales, Reuters reported.

Roche stakes its claim as the leader in high-risk Alzheimer's R&D

That dark cloud you've been watching form around the late-stage Alzheimer's drug development field has come equipped with a bright silver lining for Roche.

MorphoSys unit, Pfizer ink Slonomics pact

German biotech MorphoSys has had a busy morning. It announced today that its subsidiary Sloning BioTechnology has signed a non-exclusive license and technology transfer agreement with pharma giant

Galapagos inks development pact with MorphoSys

Shares of Belgium's Galapagos surged on the news that it had partnered with Germany's MorphoSys AG to develop antibodies for bone and joint diseases. The two companies plan to jointly invest 30